The EMA is restricting the use of Sanofi SA's multiple sclerosis (MS) drug, Lemtrada (alemtuzumab), while it reviews new reports of immune-mediated conditions and problems with the heart and blood vessels, including fatal cases, that may be associated with the monoclonal antibody.